DCGI approves Ampio Pharma’s Phase II trials to tackle Covid-19 induced respiratory distress
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Subscribe To Our Newsletter & Stay Updated